SULFAMETHOXAZOLE SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H10N3O3S.Na
Molecular Weight	275.259
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CC1=CC([N-]S(=O)(=O)C2=CC=C(N)C=C2)=NO1

InChI

InChIKey=LARLNXOUTTUXPN-UHFFFAOYSA-N

InChI=1S/C10H10N3O3S.Na/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9;/h2-6H,11H2,1H3;/q-1;+1

HIDE SMILES / InChI

Molecular Formula	C10H11N3O3S
Molecular Weight	253.278
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017377s074lbl.pdf

Sulfamethoxazole is a synthetic antibacterial drug,which is used in combination with trimethoprim (Bactrim, Septra) for the treatment or prevention of infections that are proven or strongly suspected to be caused by bacteria. Sulfamethoxazole acts by inhibiting folic acid synthesis via enzyme called dihydropteroate synthase.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial dihydropteroate synthase 44 Target ID: CHEMBL2364668 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017377s074lbl.pdf	Inhibitor 8504		0.71 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Urinary tract infections 207 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017377s074lbl.pdf	Curative	Approved 8583	BACTRIM Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Launch Date 1973
Acute otitis media 29 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017377s074lbl.pdf	Curative	Approved 8583	BACTRIM Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Launch Date 1973
Acute exacerbations of chronic bronchitis in adults 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017377s074lbl.pdf	Curative	Approved 8583	BACTRIM Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Launch Date 1973
Shigellosis 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017377s074lbl.pdf	Curative	Approved 8583	BACTRIM Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Launch Date 1973
Pneumocystis jiroveci pneumonia 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017377s074lbl.pdf	Curative	Approved 8583	BACTRIM Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Launch Date 1973
Travelers’ diarrhea 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017377s074lbl.pdf	Curative	Approved 8583	BACTRIM Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Launch Date 1973

C_max

Value	Dose	Co-administered	Analyte	Population
94.42 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20110016	1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered:		SULFAMETHOXAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
46.3 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018374s025lbl.pdf	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: TRIMETHOPRIM	TRIMETHOPRIM	SULFAMETHOXAZOLE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1202.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20110016	1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered:		SULFAMETHOXAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
12.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018374s025lbl.pdf	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: TRIMETHOPRIM	TRIMETHOPRIM	SULFAMETHOXAZOLE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
30% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018374s025lbl.pdf	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: TRIMETHOPRIM	TRIMETHOPRIM	SULFAMETHOXAZOLE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/	unhealthy, 86 years Health Status: unhealthy Age Group: 86 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/	Disc. AE: Insomnia... Other AEs: Fear, Behaviour abnormal... AEs leading to discontinuation/dose reduction: Insomnia Other AEs: Fear Behaviour abnormal Visual hallucinations Disorientation Auditory hallucinations Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/
1600 mg multiple, oral Recommended Dose: 1600 mg Route: oral Route: multiple Dose: 1600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/4936539/	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/4936539/	Other AEs: Leucopenia... Other AEs: Leucopenia Sources: https://pubmed.ncbi.nlm.nih.gov/4936539/
2400 mg 1 times / day single, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: single Dose: 2400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6724874/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-105_Zotrim_medr.pdf	unhealthy, mean age 20 years Health Status: unhealthy Age Group: mean age 20 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/6724874/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-105_Zotrim_medr.pdf	Sources: https://pubmed.ncbi.nlm.nih.gov/6724874/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-105_Zotrim_medr.pdf
1200 mg 2 times / day multiple, oral Recommended Dose: 1200 mg, 2 times / day Route: oral Route: multiple Dose: 1200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6794406/	unhealthy, mean age 47 years Health Status: unhealthy Age Group: mean age 47 years Sources: https://pubmed.ncbi.nlm.nih.gov/6794406/	Disc. AE: Allergic reaction... Other AEs: Granulocytopenia... AEs leading to discontinuation/dose reduction: Allergic reaction (3.8%) Other AEs: Granulocytopenia Sources: https://pubmed.ncbi.nlm.nih.gov/6794406/
800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4885025/	unhealthy, mean age 58 years Health Status: unhealthy Age Group: mean age 58 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4885025/	Disc. AE: Skin rash... AEs leading to discontinuation/dose reduction: Skin rash (4.9%) Sources: https://pubmed.ncbi.nlm.nih.gov/4885025/
1200 mg multiple, oral Studied dose Dose: 1200 mg Route: oral Route: multiple Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12963573/	unhealthy, median age 69 years Health Status: unhealthy Age Group: median age 69 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12963573/	Other AEs: Agranulocytosis... Other AEs: Agranulocytosis (9.9%) Sources: https://pubmed.ncbi.nlm.nih.gov/12963573/

AEs

AE	Significance	Dose	Population
Auditory hallucinations		800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/	unhealthy, 86 years Health Status: unhealthy Age Group: 86 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/
Behaviour abnormal		800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/	unhealthy, 86 years Health Status: unhealthy Age Group: 86 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/
Disorientation		800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/	unhealthy, 86 years Health Status: unhealthy Age Group: 86 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/
Fear		800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/	unhealthy, 86 years Health Status: unhealthy Age Group: 86 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/
Visual hallucinations		800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/	unhealthy, 86 years Health Status: unhealthy Age Group: 86 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/
Insomnia	Disc. AE	800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/	unhealthy, 86 years Health Status: unhealthy Age Group: 86 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/24268951/
Leucopenia		1600 mg multiple, oral Recommended Dose: 1600 mg Route: oral Route: multiple Dose: 1600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/4936539/	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/4936539/
Granulocytopenia		1200 mg 2 times / day multiple, oral Recommended Dose: 1200 mg, 2 times / day Route: oral Route: multiple Dose: 1200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6794406/	unhealthy, mean age 47 years Health Status: unhealthy Age Group: mean age 47 years Sources: https://pubmed.ncbi.nlm.nih.gov/6794406/
Allergic reaction	3.8% Disc. AE	1200 mg 2 times / day multiple, oral Recommended Dose: 1200 mg, 2 times / day Route: oral Route: multiple Dose: 1200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6794406/	unhealthy, mean age 47 years Health Status: unhealthy Age Group: mean age 47 years Sources: https://pubmed.ncbi.nlm.nih.gov/6794406/
Skin rash	4.9% Disc. AE	800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4885025/	unhealthy, mean age 58 years Health Status: unhealthy Age Group: mean age 58 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4885025/
Agranulocytosis	9.9%	1200 mg multiple, oral Studied dose Dose: 1200 mg Route: oral Route: multiple Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12963573/	unhealthy, median age 69 years Health Status: unhealthy Age Group: median age 69 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12963573/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 substrate 1946	inhibitor 2438 substrate 1193	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2C8 1057 CYP2C19 2057 CYP2E1 1060

Drug as perpetrator

Target	Modality	Activity
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 5.0	moderate [Ki 271 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0	unlikely
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0	unlikely
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0	unlikely
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0	unlikely
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0	unlikely
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0	unlikely
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0	unlikely

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/9602961/ Page: 4.0	yes
CYP2C9 1193	substrate 4014 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1046/j.1365-2125.1996.40110.x#page=3 Page: 3.0	yes		yes (co-administration study) Comment: ketoconazole did not inhibit hydroxylamine formation or any route of SMX metabolism; fluconazole decreased 5OH-SMX-acetate by64.0% Sources: https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1046/j.1365-2125.1996.40110.x#page=3 Page: 3.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:9332	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9332
ChemicalBook	CB6473303	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6473303
eMolecules	511895	https://www.emolecules.com/cgi-bin/more?vid=511895
MolPort	MolPort-000-145-787	https://www.molport.com/shop/molecule-link/MolPort-000-145-787
Selleck Chemicals	Sulfamethoxazole	http://www.selleckchem.com/products/Sulfamethoxazole.html
ZINC	ZINC000000089763	http://zinc15.docking.org/substances/ZINC000000089763

PubMed

Title	Date	PubMed
Current treatment options for chronic granulomatous disease.	2002-07	12083986
Study of different off-line sample processing procedures and the measurement of antibiotic and antiviral levels in human serum by high-performance liquid chromatography.	2002-06-25	12031842
Second derivative spectrophotometric determination of trimethoprime and sulfamethoxazole in the presence of hydroxypropyl-beta-cyclodextrin (HP-beta-CD).	2002-06-20	12062664
Sensitivity and resistance of antibiotics in common infection of male and female.	2002-06-05	12043324
[Characterization of Vibrio cholerae eltor in the city of Kazan in 2001].	2002-06-05	12043149
Ofuji's disease: a report on 20 patients with clinical and histopathologic analysis.	2002-06	12063478
Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.	2002-06	12019187
In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species.	2002-06	12019133
Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan.	2002-04-15	11914994
Quantification of veterinary antibiotics (sulfonamides and trimethoprim) in animal manure by liquid chromatography-mass spectrometry.	2002-04-05	12064522
Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport?	2002-04	12033380
Salmonella enterica serotype Typhimurium DT104 isolated from humans, United States, 1985, 1990, and 1995.	2002-04	11971772
Transfer and distribution profiles of dietary sulphonamides in the tissues of the laying hen.	2002-04	11962694
Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation.	2002-04	11956677
Pneumocystis carinii infection in bilateral aural polyps in a human immunodeficiency virus-positive patient.	2002-04	11945191
Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.	2002-04	11918724
Liquid chromatographic determination of multiple sulfonamides, nitrofurans, and chloramphenicol residues in pasteurized milk.	2002-03-07	11878601
Simultaneous dissolution profiles of two drugs in pharmaceutical formulations by an FIA manifold.	2002-03-01	11836065
Septicaemic pasteurellosis in ostriches (Struthio camelus) in central Saudi Arabia.	2002-03	12093199
Pharmacokinetics of sulfamethoxazole and trimethoprim in donkeys, mules, and horses.	2002-03	11911569
Iminodibenzyl as a novel coupling agent for the spectrophotometric determination of sulfonamide derivatives.	2002-03	11880002
Determination of anti-microbial susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis.	2002-02	12073719
Role of endotoxin in 6-sulfanilamidoindazole(6SAI)-induced arthritis in rats.	2002-02	11926286
Brucellosis in the etiology of febrile neutropenia: case report.	2002-02	11892906
Occurrence of Salmonella enterica serotype typhimurium DT104A in retail ground beef.	2002-02	11848574
Folic acid antagonism of sulfa drug treatments.	2002-02	11832284
Amniotic membrane in the surgical management of acute toxic epidermal necrolysis.	2002-02	11825823
Allergic adverse reactions to sulfonamides.	2002-01	11895621
Linkage between toxin production and purine biosynthesis in Clostridium difficile.	2002-01	11800470
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.	2002-01	11786970
Antimicrobial susceptibility of Haemophilus influenzae among children in Beijing, China, 1999-2000.	2002	11951998
Determination of selected sulfonamide antibiotics and trimethoprim in manure by electrospray and atmospheric pressure chemical ionization tandem mass spectrometry.	2002	11921244
Matrix solid-phase dispersion extraction and high-performance liquid chromatographic determination of residual sulfonamides in chicken.	2001-12-07	11765084
Bilirubin-albumin binding and free bilirubin.	2001-12	11803415
High-performance liquid chromatographic procedure for routine residue monitoring of seven sulfonamides in milk.	2001-12	11769794
Hydrogen bonding in sulfonamides.	2001-12	11745765
Resistance to trimethoprim-sulfamethoxazole and modifications in genes coding for dihydrofolate reductase and dihydropteroate synthase in European Streptococcus pneumoniae isolates.	2001-12	11733486
Vibrio cholerae O1 outbreak isolates in Mozambique and South Africa in 1998 are multiple-drug resistant, contain the SXT element and the aadA2 gene located on class 1 integrons.	2001-12	11733467
Natural antimicrobial susceptibilities of Plesiomonas shigelloides strains.	2001-12	11733464
Folic acid utilisation related to sulfa drug resistance in Saccharomyces cerevisiae.	2001-11-13	11731153
Paraplegia secondary to Burkholderia pseudomallei myelitis: a case report.	2001-11	11689986
Plasmid mediated antibiotic resistance in Klebsiella pneumoniae.	2001-10	12035355
Antimicrobial susceptibility and plasmids from Escherichia coli isolated from rats.	2001-10	11921594
Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.	2001-10	11678792
Cotrimoxazole treatment for rheumatoid arthritis.	2001-10	11590583
Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data.	2001-09	11745780
The occurrence of sinusitis in HIV-infected patients with fever.	2001-09	11721503
Practice guidelines for the treatment of uncomplicated cystitis.	2001-08	12084260
Tg.AC genetically altered mouse: assay working group overview of available data.	2001	11695563
Neonatal mouse model: review of methods and results.	2001	11695548

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage in the treatment of urinary tract infections and otitis media is 1 DS (double strength) tablet (each DS tablets contains 800 mg sulfamethoxazole and 160 mg trimethoprim) every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The recommended dose for children with urinary tract infections or acute otitis media is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis.The usual adult dosage in the treatment of acute exacerbations of chronic bronchitis is 1 DS tablet every 12 hours for 14 days. The recommended dosage for treatment of patients with documented Pneumocystis jiroveci pneumonia is 75 to 100 mg/kg sulfamethoxazole and 15 to 20 mg/kg trimethoprim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days. The recommended dosage for prophylaxis in adults is 1 DS tablet daily. For the treatment of traveler’s diarrhea, the usual adult dosage is 1 DS tablet every 12 hours for 5 days.

Route of Administration: Oral

In Vitro Use Guide

Bacterias were treated with 23.75 ug sulfamethoxazole to test the susceptibility of microorganisms. MIC values were 38 mcg/ml (Enterobacteriaceae), 9.5 mcg/ml (Haemophilus influenzae), 9.5 mcg/ml (Streptococcus pneumoniae).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:54:36 GMT 2025` Edited by `admin` on `Mon Mar 31 20:54:36 GMT 2025`
Record UNII	PJ0X8H59AI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SULFAMETHOXAZOLE SODIUM

Common Name

English

BENZENESULFONAMIDE, 4-AMINO-N-(5-METHYL-3-ISOXAZOLYL)-, SODIUM SALT (1:1)

Preferred Name

English

SULFAMETHOXAZOLE SODIUM [JAN]

Common Name

English

SODIUM N-(5-METHYLISOXAZOL-3-YL)SULPHANILAMIDATE

Systematic Name

English

SODIUM 4-AMINO-N-(5-METHYLISOXAZOL-3-YL)BENZENESULFONAMIDE

Systematic Name

English

Sulfamethoxazole sodium [WHO-DD]

Common Name

English

Code System Code Type Description

EVMPD

SUB35068